Seelos Set to Begin Animal Studies for SLS-007 Using Gene Therapy Approach

Seelos Set to Begin Animal Studies for SLS-007 Using Gene Therapy Approach
Seelos Therapeutics will begin animal studies to test a gene therapy approach to deliver its investigational candidate SLS-007 for Parkinson’s disease. SLS-007, originally developed by scientists at the University of California, Los Angeles, is intended to lessen the aggregation, or clumping, of alpha-synuclein protein — a major component of the Lewy bodies found in Parkinson’s patients. The investigational therapy consists of ... read more
Source: Parkinson’s News TodayPublished on 2020-01-30By Patricia Inacio, PhD